Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Edith Borcoman


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


E. Borcoman1, V. Lemiale2, A. Dupont3, E. Mariotte2, C. Pichereau2, L. Doucet4, A. Joseph2, A. Chermak2, S. Valade2, M. Resche-Rigon3, E. Azoulay2

Author affiliations

  • 1 Department Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 2 Medical Icu, APHP Hôpital Saint Louis, 75010 - Paris/FR
  • 3 Biostatistic Department, APHP Hôpital Saint Louis, 75010 - Paris/FR
  • 4 Department Of Medical Oncology, Hôpital Saint Louis AP-HP, 75010 - Paris/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5643


Survival of patients with solid cancer improved over the last decade. Whether this translates in survival advances when they become critically ill is uncertain. We sought to determine trends in survival over time in critically ill patients with solid tumors.


Retrospective single center cohort of patients with solid tumors admitted to ICU over a 10-year period. Factors independently associated with day-30 and 1-year mortality after ICU discharge were identified.


A total of 669 patients were admitted. Primary site of cancer was lung (21%), digestive (20%) and breast cancer (19%); 335 patients (54%) had metastasis. A decision to withhold/withdraw life sustaining therapies was implemented in 158 (25%) patients. ICU, Day-30 and one-year mortality were 23%, 35% and 41%. Among the 484 (77%) ICU survivors, 248 (39%) actually underwent an oncologic treatment following ICU discharge. Factors associated with day-30 mortality included: the period of ICU admission (HR = 0.7, p = 0.03 after 2010 vs before 2010), poor performance status (>2) (HR = 1.4, p = 0.03), metastatic stage of cancer (vs localized cancer) (HR = 2.1, p = 0.002), need for mechanical ventilation (HR = 4.5, p < 0.0001, or vasopressors (HR = 2.3, p = 0.0003). Decisions for forgo life-sustaining therapy in ICU were also associated with day-30 mortality (HR = 3.3, p < 0.0001). Factors associated with 1-year mortality included ICU admission after 2010 (HR 0.5, p < 0.001), locally advanced (HR = 1.8, p = 0.002) or metastatic cancer (HR = 2.2, p = 0.002), poor performance status (HR = 1.5, p = 0.01), newly diagnosed cancer at ICU admission (HR = 2.0, p = 0.003) the inability to receive a cancer treatment after ICU discharge (HR = 5.3, p < 0.001) and decisions to forgo life-sustaining therapy throughout ICU stay (HR = 2.3, p < 0.001).


In critically-ill oncology patients, survival improves over time. Tumor staging and performance status impact on both short-term and long-term mortality suggesting that the goals of care should be better fine-tuned in the future. Most importantly, patient’s ability to receive cancer treatment and oncologist willingness to provide optimal cancer management are major determinants of 1-year mortality.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

E. Azoulay.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.